EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer

BACKGROUND: Cisplatin-based chemotherapy is recommended as the primary treatment for advanced bladder cancer (BC) with unresectable or metastatic disease. However, the benefits are limited due to the acquisition of drug resistance. The mechanisms of resistance remain unclear. Although there are some...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Okamura, Shunsuke, Yoshino, Hirofumi, Kuroshima, Kazuki, Tsuruda, Masafumi, Osako, Yoichi, Sakaguchi, Takashi, Yonemori, Masaya, Yamada, Yasutoshi, Tatarano, Shuichi, Nakagawa, Masayuki, Enokida, Hideki
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7798329/
https://ncbi.nlm.nih.gov/pubmed/33430801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07717-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados